[1] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012. CA Cancer J Clin,2015,65:87-108.
[2] 薛雨墨,姚博文,刘志奎,等.NANOG在肝细胞癌中的表达及意义.西安交通大学学报(医学版),2016,37:684-688.
[3] 张强.原发性肝细胞癌中HMGB1的表达与临床分析. 临床医药文献电子杂志,2016,3:683-684.
[4] 黄风玲,杨颖,张瑞丽,等.肝细胞癌组织中高尔基体蛋白73和转化生长因子β1及Smad2的表达水平及其意义.中国全科医学,2016,19:3191-3195.
[5] 陆雄,郝福军,葸根,等. miR-21通过下调PTEN表达促进肝癌细胞增殖、侵袭及迁移.延安大学学报:医学科学版,2016,14:1-5.
[6] 周宝勇,蒋宁,廖锐,等. LETM1在肝癌中的表达及其对SMMC-7721细胞增殖和凋亡的影响.第三军医大学学报,2016,38:1942-1947.
[7] 李文柱.罗宁斌,苏丹柯,等.能谱CT预测肝细胞癌微血管侵犯的可行性研究.医学影像学杂志,2016,26:212~216.
[8] 吴碧君,谢佳佳,周苏晋,等.彩色多普勒超声诊断肝内门-体静脉分流价值探讨.实用肝脏病杂志,2015,18:391-394.
[9] 佟桂玲.MRI门脉造影在恶性肝病预后的评估作用.中国CT和MRI杂志,2016,14:37-39.
[10] Wu D,Tan M,Zhou M,et al. Liver computed tomographic perfu- sion in the assessment of microvascular invasion in patients with small hepatocellular carcinoma. Invest Radiol,2015,50:188-194.
[11] Banerjee S,Wang DS,Kim HJ,et al. A computedtomography radiogenomic biomarker predicts microvascularinvasion and clinical outcomes in hepatocellular carcinoma. Hepatology,2015,62:792-800.
[12] 邵艳,管静芝.原发性肝癌治疗进展.传染病信息,2016,29:248-252.
[13] Colliez F,Fruytier AC,Magat J,et al. Monitoring combretastatin A4-induced tumor hypoxiaand hemodynamic changes using endogenous MR contrast and DCE-MRI. Magn Reson Med,2016,75:866-872.
[14] Jiang L,Yu H,Xiao BC,et al. Sorafenib after resection improvesthe outcomes of BCLC stage C hepatocellular carcinoma.World J Gastroenterol,2016,22:4034-4040.
[15] 张黎,梁健,孙文钊,等.原发性肝癌伴门脉癌栓立体定向放射治疗的疗效分析.中山大学学报(医学科学版),2015,36: 579-584.
[16] Lee SU,Park JW,Kim TH,et al. Effectiveness and safety of protonbeam therapy for advanced hepatocellular carcinoma with portalvein tumor thrombosis. Strahlenther Onkol,2014,190:806-814.
[17] 陆辉荣,黄尚校,梁世雄,等.原发性肝癌合并门脉癌栓放射治疗的预后分析.微创医学,2015,10:131-135.
[18] Yang M,Fang Z,Yan Z,et al.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm,randomised clinical trial. J Cancer Res Clin Oncol,2014,140:211-219.
[19] Chung SM,Yoon CJ,Lee SS,et al. Treatment outcomes of tran-scatheter arterial chemoembolization for hepatocellular carcinomathat invades hepatic vein or inferior vena cava. Cardiovasc In-tervent Radiol,2014,37:1507-1515.
[20] 谭凯,杜锡林,杨涛,等.肝癌合并门脉癌栓术后门脉化疗疗效分析.西部医学,2015,13:989-991.
[21] 吴俣,张志伟,高丹,等.大肝癌伴门脉癌栓病人综合疗法选择对照研究.中国实用外科杂志,2014,34:757-761. |
